Rapid Micro Biosystems (NASDAQ:RPID) Posts Earnings Results, Misses Expectations By $0.03 EPS

Rapid Micro Biosystems (NASDAQ:RPID) announced its quarterly earnings results on Friday. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03), FiscalAI reports. The business had revenue of $8.05 million during the quarter, compared to the consensus estimate of $7.88 million. Rapid Micro Biosystems had a negative net margin of 145.81% and a negative return on equity of 131.52%.

Here are the key takeaways from Rapid Micro Biosystems’ conference call:

• Second-quarter revenue rose 11% year over year to $8.1 million, exceeding guidance, with four Growth Direct Systems placed and nine validations completed. The company reached its 200th system placement milestone and reported record quarterly consumable revenue.
• Recurring revenue increased 14% to $5.0 million, supported by a larger installed base and higher system utilization, while consumable revenue grew more than 20%. Management expects further consumable and service growth in the second half.
• Gross margin improved to a record 15% from 4% a year earlier, driven by cost reductions, manufacturing efficiencies, service productivity, and operating leverage. The company expects at least 20% gross margin in Q3 and mid- to high-20% margins in Q4.
• Rapid Micro reaffirmed 2026 revenue guidance of $37 million to $41 million and system-placement guidance of 30 to 38 systems, while raising validation guidance to at least 27 systems. Management also expects a meaningfully stronger contribution from its MilliporeSigma collaboration in the second half.
• The company reported a $12.9 million quarterly net loss and ended the quarter with approximately $20 million in cash and short-term investments. Although cash usage is expected to decline, Rapid Micro remains dependent on cost reductions, improved operating performance, potential debt-facility tranches, and warrant proceeds to support its path to positive cash flow.

Rapid Micro Biosystems Stock Performance

Shares of NASDAQ RPID traded down $0.35 during midday trading on Friday, reaching $1.73. The company’s stock had a trading volume of 1,443,479 shares, compared to its average volume of 204,342. Rapid Micro Biosystems has a 12-month low of $1.66 and a 12-month high of $4.94. The firm has a 50 day moving average price of $1.90 and a 200-day moving average price of $2.67. The stock has a market capitalization of $79.87 million, a P/E ratio of -1.54 and a beta of 1.44. The company has a debt-to-equity ratio of 0.93, a current ratio of 2.57 and a quick ratio of 1.66.

Institutional Trading of Rapid Micro Biosystems

A number of hedge funds have recently bought and sold shares of the business. Millennium Management LLC bought a new position in Rapid Micro Biosystems in the 4th quarter valued at $338,000. 683 Capital Management LLC bought a new stake in Rapid Micro Biosystems in the fourth quarter worth about $350,000. OMERS ADMINISTRATION Corp bought a new stake in Rapid Micro Biosystems in the fourth quarter worth about $71,000. Barclays PLC purchased a new position in Rapid Micro Biosystems in the fourth quarter valued at about $72,000. Finally, Marshall Wace LLP purchased a new position in Rapid Micro Biosystems in the fourth quarter valued at about $182,000. 52.60% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

RPID has been the subject of several analyst reports. KeyCorp lowered their price objective on Rapid Micro Biosystems from $8.00 to $5.00 and set an “overweight” rating for the company in a research note on Friday, May 29th. Wall Street Zen raised Rapid Micro Biosystems from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Friday, July 17th. Finally, Lake Street Capital cut their price objective on shares of Rapid Micro Biosystems from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, May 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $6.00.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.